Inhibiteur STAT3 III; WP1066

Non disponible en dehors du Royaume-Uni et de l'Irlande

Biochem/physiol Actions

Reversible: no

Primary TargetSTAT3 pathway

Product does not compete with ATP.

Target IC₅₀: 5.6 and 3.7 µM in inhibiting malignant glioma growth in a viability assay using U87-MG and U373-MG, respectively

Cell permeable: yes

General description

A cell-permeable AG 490 (Cat. No. 658401) tyrphostin analog that acts as an effective STAT3 pathway inhibitor and a much more potent antitumor agent than AG 490 in inhibiting malignant glioma growth both in cultures in vitro (IC₅₀ = 5.6 and 3.7 µM in a viability assay using U87-MG and U373-MG, respectively; no inhibition against nontumor NHA at 10 µM) and in mice in vivo. Shown to cross blood-brain barrier in mice in vivo.

A cell-permeable AG 490 (Cat. No. 658401) tyrphostin analog that acts as an effective STAT3 pathway inhibitor and a much more potent antitumor agent than AG 490 in inhibiting malignant glioma growth both in cultures in vitro (IC₅₀ = 5.6 and 3.7 µM in a viability assay using U87-MG and U373-MG, respectively; no inhibition against nontumor NHA at 10 µM) and in mice in vivo. Shown to cross blood-brain barrier in mice in vivo. Also available in InSolution™ format (Cat. No. 573129.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Other Notes

Iwamaru, A., et al. 2007. Oncogene,26, 2435.

Packaging

Packaged under inert gas

10 mg in Glass bottle

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 6 months at -20°C.

Warning

Toxicity: Irritant (B)